2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
133 hedge funds and large institutions have $478M invested in 2seventy bio in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 16 closing their positions.
309% more call options, than puts
Call options by funds: $2.26M | Put options by funds: $552K
10% more capital invested
Capital invested by funds: $436M → $478M (+$42.4M)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
1% more funds holding
Funds holding: 132 → 133 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$15.5M |
| 2 |
Goldman Sachs
New York
|
+$10.7M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$4.82M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.55M |
| 5 |
Millennium Management
New York
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$17.1M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$6.99M |
| 3 |
NM
Newtyn Management
New York
|
-$5.89M |
| 4 |
AC
Armistice Capital
New York
|
-$4.99M |
| 5 |
MAP
Madison Avenue Partners
New York
|
-$4.62M |
TSVT Hedge Fund Activity: Q3 2022 in Review
133 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q3 2022, worth a combined $478M — up 9.7% from $436M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TSVT positions and 16 closed out — a net gain of 1 holder — while 37 added to existing stakes and 36 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $15.5M. The largest seller was EcoR1 Capital, cutting an estimated $17.1M.
- 133 institutional investors held 2seventy bio (TSVT) as of Q3 2022, up from 132 in Q2 2022.
- Funds reported $478M of 2seventy bio stock for Q3 2022, up 9.7% quarter-over-quarter.
- 17 funds opened new 2seventy bio positions in Q3 2022 and 16 closed out, a net change of +1 holder.
- The largest 2seventy bio buyer in Q3 2022 was OrbiMed, an estimated $15.5M added.
- The largest 2seventy bio seller in Q3 2022 was EcoR1 Capital, an estimated $17.1M sold.
Based on aggregated 13F filings for Q3 2022.